224
Participants
Start Date
October 1, 2024
Primary Completion Date
May 2, 2025
Study Completion Date
May 12, 2025
BI 1569912
BI 1569912
Placebo matching BI 1569912
Placebo matching BI 1569912
Berman Clinical, New York
Davis Clinical, The Bronx
Integrative Clinical Trials LLC, Brooklyn
Neurobehavioral Research, Inc., Cedarhurst
Surburban Research Associates, Inc., Media
Pharmasite Research, Incorporated, Baltimore
iResearch Atlanta, Decatur
Psych Atlanta, PC, Marietta
Advanced Discovery Research LLC, Atlanta
Clinical Neuroscience Solutions, Inc-Jacksonville-62642, Jacksonville
Clinical Neuroscience Solutions, Inc-Orlando-62685, Orlando
Research Centers of America-Hollywood-67537, Hollywood
CCM Clinical Research Group, LLC-Miami-68482, Miami
Optimus U Corporation-Miami-69452, Miami
Clinical Neuroscience Solutions, Inc-Memphis-65988, Memphis
Psychiatric Care and Research Center, O'Fallon
Sooner Clinical Research, Inc, Oklahoma City
FutureSearch Trials of Dallas, LP, Dallas
Grayline Research Center, Wichita Falls
Clinical Innovations, Inc, Bellflower
ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach
California Neuroscience Research, Sherman Oaks
Pacific Clinical Research Management Group LLC, Upland
Excell Research Inc., Oceanside
Artemis Institute for Clinical Research, LLC, San Diego
CiTrials-Riverside-63180, Riverside
Lumos Clinical Research, San Jose
Northwest Clinical Research Center, Bellevue
Core Clinical Research, Everett
Copley Clinical, Boston
Boston Clinical Trials, Roslindale
Adams Clinical, Watertown
ActivMed, Portsmouth
Center For Emotional Fitness, Cherry Hill
Bio Behavioral Health, Toms River
Uematsu Mental Clinic, Fukuoka, Chikugo
Kaku Mental Clinic, Fukuoka, Fukuoka
Hirota Clinic, Fukuoka, Kurume
Yutaka Clinic, Kanagawa,Sagamihara
Maynds Tower Mental Clinic, Tokyo, Shibuya-ku
Ichigaya Himorogi Clinic, Tokyo, Shinjuku-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY